Literature DB >> 34985914

eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems.

Michael J Hassett1, Christine Cronin1, Terrence C Tsou2, Jason Wedge3, Jessica Bian4, Don S Dizon5, Hannah Hazard-Jenkins6, Raymond U Osarogiagbon7, Sandra Wong8, Ethan Basch9, Toby Austin3, Nadine McCleary1, Deborah Schrag10.   

Abstract

PURPOSE: Collecting patient-reported outcomes (PROs) can improve symptom control and quality of life, enhance doctor-patient communication, and reduce acute care needs for patients with cancer. Digital solutions facilitate PRO collection, but without robust electronic health record (EHR) integration, effective deployment can be hampered by low patient and clinician engagement and high development and deployment costs. The important components of digital PRO platforms have been defined, but procedures for implementing integrated solutions are not readily available.
METHODS: As part of the NCI's IMPACT consortium, six health care systems partnered with Epic to develop an EHR-integrated, PRO-based electronic symptom management program (eSyM) to optimize postoperative recovery and well-being during chemotherapy. The agile development process incorporated user-centered design principles that required engagement from patients, clinicians, and health care systems. Whenever possible, the system used validated content from the public domain and took advantage of existing EHR capabilities to automate processes.
RESULTS: eSyM includes symptom surveys on the basis of the PRO-Common Terminology Criteria for Adverse Events (PRO-CTCAE) plus two global wellness questions; reminders and symptom self-management tip sheets for patients; alerts and symptom reports for clinicians; and population management dashboards. EHR dependencies include a secure Health Insurance Portability and Accountability Act-compliant patient portal; diagnosis, procedure and chemotherapy treatment plan data; registries that identify and track target populations; and the ability to create reminders, alerts, reports, dashboards, and charting shortcuts.
CONCLUSION: eSyM incorporates validated content and leverages existing EHR capabilities. Build challenges include the innate technical limitations of the EHR, the constrained availability of site technical resources, and sites' heterogenous EHR configurations and policies. Integration of PRO-based symptom management programs into the EHR could help overcome adoption barriers, consolidate clinical workflows, and foster scalability and sustainability. We intend to make eSyM available to all Epic users.

Entities:  

Mesh:

Year:  2022        PMID: 34985914     DOI: 10.1200/CCI.21.00137

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  3 in total

1.  Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial.

Authors:  Michael J Hassett; Sandra Wong; Raymond U Osarogiagbon; Jessica Bian; Don S Dizon; Hannah Hazard Jenkins; Hajime Uno; Christine Cronin; Deborah Schrag
Journal:  Trials       Date:  2022-06-16       Impact factor: 2.728

2.  Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study.

Authors:  Jody Underwood; Ann Raldow; Amar Kishan; Chad Zalkin; Lisa Scott Holt; Andrew Webb; Kathleen A Lynch; Thomas M Atkinson; Susan McCloskey; Daniel Navarro
Journal:  JMIR Form Res       Date:  2022-04-12

3.  Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.

Authors:  Yun Jiang; Madilyn Mason; Youmin Cho; Ankita Chittiprolu; Xingyu Zhang; Karen Harden; Yang Gong; Marcelline R Harris; Debra L Barton
Journal:  BMC Cancer       Date:  2022-09-03       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.